comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 00:52:30 - browse：6

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： First Opinion Podcast: How to protect health care in times of war

focus

WSS

How medical schools plan to diversify without affirmative action

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

FDA panel endorses Alnylam’s heart drug — after picking it apart

Senate panel to vote on hospitals, PBMs, prisoner care

Regeneron agrees to White House price limits on anti

Acelyrin, a rare IPO success, stumbles in its first big test

entertainment

comprehensive

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Guidelines to prevent youth baseball injuries need more muscle

FDA approves updated Covid vaccines

What does generative AI mean for health care? We asked experts

FDA proposes changes to key medical devices approval pathway

Tori Bowie and the unacceptable rates of Black maternal death

Senate panel to vote on hospitals, PBMs, prisoner care

Supreme Court strikes down use of affirmative action

CDC recommends rationing of RSV shot due to shortages

entertainment

What to make of Biden’s latest efforts on cancer research

Traditional Chinese medicine benefits explored in new JAMA study

Walmart eyes Medicare Advantage provider ChenMed

FDA has safety concerns on CRISPR

Long Covid needs a new name — and a new frame

Emergency medicine has repudiated 'excited delirium.' Now what?

Wikipedia

focus

entertainment

focus